Keywords: novartis, glivec, approved, europe, cut, gist, recurrence

Novartis' Glivec approved in Europe to cut GIST recurrence

Article | 11 May 2009

Print This

Swiss drug major Novartis' Glivec (imatinib) received approval from the European Commission to become the first and only treatment available ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in